Literature DB >> 23596249

Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.

Michael J Rybak1, Celine Vidaillac, Helio S Sader, Paul R Rhomberg, Hossein Salimnia, Lawrence E Briski, Audrey Wanger, Ronald N Jones.   

Abstract

We evaluated the ability of four commercial MIC testing systems (MicroScan, Vitek 2, Phoenix, and Etest) to detect vancomycin MIC values of ≤1 to ≥2 in 200 methicillin-resistant Staphylococcus aureus (MRSA) strains compared to the Clinical and Laboratory Standards Institute broth microdilution (BMD) reference methods. Compared to the BMD method, absolute agreement (0 ± dilution) was highest for the Phoenix system (66.2%) and the MicroScan turbidity method (61.8%), followed by the Vitek 2 system (54.3%). The Etest produced MIC values 1 to 2 dilutions higher than those produced by the BMD method (36.7% agreement). Of interest, the MicroScan system (prompt method) was more likely to overcall an MIC value of 1 mg/liter (74.1%), whereas the Phoenix (76%) and Vitek 2 (20%) systems had a tendency to undercall an MIC of 2 mg/liter. The ability to correctly identify vancomycin MIC values of 1 and 2 has clinical implications and requires further evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596249      PMCID: PMC3697692          DOI: 10.1128/JCM.00448-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

2.  Methicillin-resistant Staphylococcus aureus and vancomycin: minimum inhibitory concentration matters.

Authors:  Stan Deresinski
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

Review 3.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

4.  Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Benjamin P Howden; Paul D R Johnson; Peter B Ward; Timothy P Stinear; John K Davies
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  Evaluation of Alamar colorimetric broth microdilution susceptibility testing method for staphylococci and enterococci.

Authors:  C N Baker; F C Tenover
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

Review 6.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

7.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

8.  Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  John F Mohr; Barbara E Murray
Journal:  Clin Infect Dis       Date:  2007-05-04       Impact factor: 9.079

9.  Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.

Authors:  Matthew R Moore; Françoise Perdreau-Remington; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.

Authors:  David Styers; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-09       Impact factor: 3.944

View more
  25 in total

1.  Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Adjunctive mecA PCR for routine detection of methicillin susceptibility in clinical isolates of coagulase-negative staphylococci.

Authors:  Chandanjit Kaur Nijjar; Melvyn Howard Smith; Ian Joseph Eltringham
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

Review 3.  [Pitfalls in determining resistance].

Authors:  A C Rodloff
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-04       Impact factor: 0.840

4.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

5.  Reproducible measurement of vancomycin MICs within the susceptible range in Staphylococcus aureus by a broth microdilution method with a "quasi-continuum" gradient of antibiotic concentrations.

Authors:  R Falcón; E M Mateo; A Talaya; E Giménez; V Vinuesa; M Á Clari; D Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-07-25       Impact factor: 3.267

6.  Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Authors:  Sara L Revolinski; Christopher D Doern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

7.  Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.

Authors:  Sandra S Richter; Daniel J Diekema; Kristopher P Heilmann; Cassie L Dohrn; Emily K Crispell; Fathollah Riahi; Jennifer S McDanel; Sarah W Satola; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

8.  Methicillin Resistant Staphylococcus aureus: Inconsistencies in Vancomycin Susceptibility Testing Methods, Limitations and Advantages of each Method.

Authors:  Charu Agrawal; Molly Madan; Anita Pandey; Bhaskar Thakuria
Journal:  J Clin Diagn Res       Date:  2015-10-01

9.  The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).

Authors:  Thomas P Lodise; Susan L Rosenkranz; Matthew Finnemeyer; Scott Evans; Matthew Sims; Marcus J Zervos; C Buddy Creech; Pratish C Patel; Michael Keefer; Paul Riska; Fernanda P Silveira; Marc Scheetz; Richard G Wunderink; Martin Rodriguez; John Schrank; Susan C Bleasdale; Sara Schultz; Michelle Barron; Ann Stapleton; Dannah Wray; Henry Chambers; Vance G Fowler; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

10.  Semi-Automated Visualization and ANalysis of Trends: A "SAVANT" for Facilitating Antimicrobial Stewardship Using Antistaphylococcal Resistance and Consumption as a Prototype.

Authors:  Robert J Clifford; Uzo Chukwuma; Michael E Sparks; Douglas Richesson; Charlotte V Neumann; Paige E Waterman; Jacob Moran-Gilad; Michael D Julius; Mary K Hinkle; Emil P Lesho
Journal:  Open Forum Infect Dis       Date:  2018-03-23       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.